ArticleInternational journal of general medicine2025
Feasibility of Absent in Melanoma 2 as a Serological Marker in Relation to Complicated Community-Acquired Pneumonia in Children: A Prospective Cohort Study.
Article in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Absent in melanoma 2 (AIM2) is associated with inflammation. We intended to determine whether serum AIM2 levels are related to severity and complications of community-acquired pneumonia (CAP) in children. Methods: In this prospective cohort study, serum AIM2 levels were measured in 305 children with CAP and in 100 healthy controls at the Hangzhou Children's Hospital between January 2022 and June 2023. CAP severity was assessed using the pediatric critical illness score (PCIS) and clinical pulmonary infection score (CPIS). In-hospital complicated CAP was identified as the outcome variable. Univariate and multivariate analyses were sequentially performed to determine the correlation between severity, outcome and serum AIM2 levels. Results: Children with CAP had higher serum AIM2 levels than controls (median, 1.45 ng/mL versus 0.36 ng/mL; P<0.001). Serum AIM2 levels in diseased children were independently correlated with PCIS (beta=-0.020; P=0.001) and CPIS (beta=0.092; P=0.002), were linearly related to likelihood of complicated CAP (P for nonlinear =0.057), and were independently associated with complicated CAP (odds ratio= 6.162; P=0.005). The outcome association was robust by calculating the E-value at 11.8 and was not moderated by age, sex, weight and more (all P interaction >0.05). Serum AIM2 levels and two independent predictors, PCIS and CPIS, were integrated to construct the model. The model was pictorially represented by the nomogram and exhibited satisfactory discrimination capability, validity, and stability under the receiver operating characteristic (ROC) curve, decision curve, and calibration curve. By computing the net reclassification improvement and integrated discrimination improvement indices and comparing the area under the ROC curve, the model significantly outperformed the combination of the PCIS and CPIS. Conclusion: Markedly enhanced serum AIM2 levels following CAP in children are highly linked to severity and complicated CAP, substantializing serum AIM2 as a biochemical metric for assessing the severity and identifying adverse outcomes of childhood CAP.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.